CNS-focused biotech Tortugas raised substantial venture capital to advance a portfolio of neurology compounds sourced through licensing from Eisai and Hansoh. The disclosed funding totaled $106 million across seed and Series A rounds, with the company planning multiple clinical programs spanning schizophrenia, tinnitus, focal epilepsy, and reversible encephalopathies. The funding package also emphasizes Tortugas’ parallel development strategy, positioning multiple independent mechanisms to test across related CNS indications. For investors, the structure suggests an intent to use the derisked mechanism-of-action thesis while building broader conditional optionality for future label expansions. In a separate industrial update, Tempus AI also deepened university collaboration efforts by signing an agreement with USC to provide molecular diagnostics, genomic profiling, and trial-matching and clinical AI tools for USC’s Keck School of Medicine and Keck Medicine hospital system. Together, these moves show both financing velocity in CNS biotech and continued enterprise traction for AI-enabled precision medicine infrastructure.